# Efficacy and Safety of Changkang Granule in the Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

> **NCT04492787** · PHASE2 · COMPLETED · sponsor: **Tasly Pharmaceutical Group Co., Ltd** · enrollment: 240 (actual)

## Conditions studied

- Irritable Bowel Syndrome with Diarrhea

## Interventions

- **DRUG:** Changkang Granule
- **DRUG:** Changkang Placebo Granule

## Key facts

- **NCT ID:** NCT04492787
- **Lead sponsor:** Tasly Pharmaceutical Group Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-06
- **Primary completion:** 2022-04-21
- **Final completion:** 2022-04-21
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2024-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04492787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04492787, "Efficacy and Safety of Changkang Granule in the Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04492787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*